ID   PROD_HUMAN              Reviewed;         600 AA.
AC   O43272; A6NF53; O14680; Q0P507; Q147W8; Q504W1; Q59FI8; Q6NV86;
AC   Q9UF13;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 3.
DT   10-MAY-2017, entry version 162.
DE   RecName: Full=Proline dehydrogenase 1, mitochondrial {ECO:0000305};
DE            EC=1.5.5.2 {ECO:0000269|PubMed:15662599};
DE   AltName: Full=Proline oxidase;
DE   AltName: Full=Proline oxidase 2;
DE   AltName: Full=p53-induced gene 6 protein;
DE   Flags: Precursor;
GN   Name=PRODH {ECO:0000312|HGNC:HGNC:9453};
GN   Synonyms=PIG6, POX2, PRODH2 {ECO:0000303|PubMed:11891283};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=9385373; DOI=10.1007/s004390050589;
RA   Campbell H.D., Webb G.C., Young I.G.;
RT   "A human homologue of the Drosophila melanogaster sluggish-A (proline
RT   oxidase) gene maps to 22q11.2, and is a candidate gene for type-I
RT   hyperprolinaemia.";
RL   Hum. Genet. 101:69-74(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Cerebellum, and Kidney;
RX   PubMed=10192398; DOI=10.1038/7777;
RA   Gogos J.A., Santha M., Takacs Z., Beck K.D., Luine V., Lucas L.R.,
RA   Nadler J.V., Karayiorgou M.;
RT   "The gene encoding proline dehydrogenase modulates sensorimotor gating
RT   in mice.";
RL   Nat. Genet. 21:434-439(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, COFACTOR,
RP   VARIANTS VAL-167 AND ARG-521, CHARACTERIZATION OF VARIANTS HYRPRO1
RP   MET-289; ASN-426; MET-427; HIS-431; PRO-441; CYS-453; SER-455; THR-472
RP   AND ARG-521, CHARACTERIZATION OF VARIANTS SCZD4 LEU-406 AND MET-466,
RP   AND CHARACTERIZATION OF VARIANTS VAL-167; TRP-185; GLN-185 AND
RP   GLU-521.
RC   TISSUE=Kidney;
RX   PubMed=15662599; DOI=10.1086/428142;
RA   Bender H.-U., Almashanu S., Steel G., Hu C.-A., Lin W.-W., Willis A.,
RA   Pulver A., Valle D.;
RT   "Functional consequences of PRODH missense mutations.";
RL   Am. J. Hum. Genet. 76:409-420(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ARG-521.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 337-600 (ISOFORMS 1/2/3).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 444-600, AND INDUCTION BY TP53.
RX   PubMed=9305847; DOI=10.1038/38525;
RA   Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B.;
RT   "A model for p53-induced apoptosis.";
RL   Nature 389:300-306(1997).
RN   [8]
RP   VARIANTS HYRPRO1 MET-289; HIS-431; PRO-441; CYS-453; SER-455; THR-472
RP   AND ARG-521, AND INVOLVEMENT IN HYRPRO1.
RX   PubMed=12217952; DOI=10.1093/hmg/11.19.2243;
RA   Jacquet H., Raux G., Thibaut F., Hecketsweiler B., Houy E.,
RA   Demilly C., Haouzir S., Allio G., Fouldrin G., Drouin V., Bou J.,
RA   Petit M., Campion D., Frebourg T.;
RT   "PRODH mutations and hyperprolinemia in a subset of schizophrenic
RT   patients.";
RL   Hum. Mol. Genet. 11:2243-2249(2002).
RN   [9]
RP   VARIANTS SCZD4 LEU-406; MET-427; PRO-441; CYS-453; MET-466; THR-472
RP   AND ARG-521, AND INVOLVEMENT IN SCZD4.
RX   PubMed=11891283; DOI=10.1073/pnas.042700699;
RA   Liu H., Heath S.C., Sobin C., Roos J.L., Galke B.L., Blundell M.L.,
RA   Lenane M., Robertson B., Wijsman E.M., Rapoport J.L., Gogos J.A.,
RA   Karayiorgou M.;
RT   "Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual
RT   pattern and increases susceptibility to schizophrenia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:3717-3722(2002).
RN   [10]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-488.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [11]
RP   VARIANTS ASN-275 AND ASP-444, AND VARIANT HYRPRO1 HIS-431.
RX   PubMed=17135275; DOI=10.1093/hmg/ddl443;
RA   Raux G., Bumsel E., Hecketsweiler B., van Amelsvoort T., Zinkstok J.,
RA   Manouvrier-Hanu S., Fantini C., Breviere G.-M.M., Di Rosa G.,
RA   Pustorino G., Vogels A., Swillen A., Legallic S., Bou J.,
RA   Opolczynski G., Drouin-Garraud V., Lemarchand M., Philip N.,
RA   Gerard-Desplanches A., Carlier M., Philippe A., Nolen M.C., Heron D.,
RA   Sarda P., Lacombe D., Coizet C., Alembik Y., Layet V., Afenjar A.,
RA   Hannequin D., Demily C., Petit M., Thibaut F., Frebourg T.,
RA   Campion D.;
RT   "Involvement of hyperprolinemia in cognitive and psychiatric features
RT   of the 22q11 deletion syndrome.";
RL   Hum. Mol. Genet. 16:83-91(2007).
CC   -!- FUNCTION: Converts proline to delta-1-pyrroline-5-carboxylate.
CC   -!- CATALYTIC ACTIVITY: L-proline + a quinone = (S)-1-pyrroline-5-
CC       carboxylate + a quinol. {ECO:0000269|PubMed:15662599}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:15662599};
CC   -!- PATHWAY: Amino-acid degradation; L-proline degradation into L-
CC       glutamate; L-glutamate from L-proline: step 1/2.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O43272-4; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43272-2; Sequence=VSP_021848;
CC       Name=3;
CC         IsoId=O43272-1; Sequence=VSP_040848, VSP_040849;
CC   -!- TISSUE SPECIFICITY: Expressed in lung, skeletal muscle and brain,
CC       to a lesser extent in heart and kidney, and weakly in liver,
CC       placenta and pancreas.
CC   -!- INDUCTION: During p53/TP53-induced apoptosis.
CC       {ECO:0000269|PubMed:9305847}.
CC   -!- DISEASE: Hyperprolinemia 1 (HYRPRO1) [MIM:239500]: An inborn error
CC       of proline metabolism resulting in elevated levels of proline in
CC       the plasma and urine. The disorder is generally benign and most
CC       affected individuals are clinically asymptomatic. Some patients,
CC       however, have neurologic manifestations, including epilepsy and
CC       mental retardation. Association with certain forms of
CC       schizophrenia have been reported. {ECO:0000269|PubMed:12217952,
CC       ECO:0000269|PubMed:15662599, ECO:0000269|PubMed:17135275}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Schizophrenia 4 (SCZD4) [MIM:600850]: A complex,
CC       multifactorial psychotic disorder or group of disorders
CC       characterized by disturbances in the form and content of thought
CC       (e.g. delusions, hallucinations), in mood (e.g. inappropriate
CC       affect), in sense of self and relationship to the external world
CC       (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g
CC       bizarre or apparently purposeless behavior). Although it affects
CC       emotions, it is distinguished from mood disorders in which such
CC       disturbances are primary. Similarly, there may be mild impairment
CC       of cognitive function, and it is distinguished from the dementias
CC       in which disturbed cognitive function is considered primary. Some
CC       patients manifest schizophrenic as well as bipolar disorder
CC       symptoms and are often given the diagnosis of schizoaffective
CC       disorder. {ECO:0000269|PubMed:11891283,
CC       ECO:0000269|PubMed:15662599}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the proline oxidase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC39529.1; Type=Frameshift; Positions=540, 563, 568, 577, 580, 582; Evidence={ECO:0000305};
CC       Sequence=AAH68260.1; Type=Frameshift; Positions=123; Evidence={ECO:0000305};
CC       Sequence=AAH94736.1; Type=Frameshift; Positions=40; Evidence={ECO:0000305};
CC       Sequence=AAH94736.1; Type=Miscellaneous discrepancy; Note=Artifact. Missing internal sequence that doesn't correspond to an exon-intron boundary.; Evidence={ECO:0000305};
CC       Sequence=BAD92709.1; Type=Miscellaneous discrepancy; Note=Intron retention. Includes intronic sequence at the 5' end.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U82381; AAB88789.1; -; mRNA.
DR   EMBL; AF120278; AAD24775.1; -; mRNA.
DR   EMBL; U79754; AAF21464.1; -; mRNA.
DR   EMBL; AC007326; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC068260; AAH68260.1; ALT_FRAME; mRNA.
DR   EMBL; BC094736; AAH94736.1; ALT_SEQ; mRNA.
DR   EMBL; BC118597; AAI18598.1; -; mRNA.
DR   EMBL; BC121809; AAI21810.1; -; mRNA.
DR   EMBL; AB209472; BAD92709.1; ALT_SEQ; mRNA.
DR   EMBL; AF010310; AAC39529.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS13754.1; -. [O43272-4]
DR   CCDS; CCDS56223.1; -. [O43272-2]
DR   RefSeq; NP_001182155.1; NM_001195226.1. [O43272-2]
DR   RefSeq; NP_057419.4; NM_016335.4.
DR   UniGene; Hs.517352; -.
DR   ProteinModelPortal; O43272; -.
DR   BioGrid; 111609; 7.
DR   STRING; 9606.ENSP00000349577; -.
DR   DrugBank; DB06756; Glycine betaine.
DR   DrugBank; DB00172; L-Proline.
DR   iPTMnet; O43272; -.
DR   PhosphoSitePlus; O43272; -.
DR   BioMuta; PRODH; -.
DR   EPD; O43272; -.
DR   PaxDb; O43272; -.
DR   PeptideAtlas; O43272; -.
DR   PRIDE; O43272; -.
DR   Ensembl; ENST00000357068; ENSP00000349577; ENSG00000100033.
DR   GeneID; 5625; -.
DR   KEGG; hsa:5625; -.
DR   UCSC; uc062bjw.1; human. [O43272-4]
DR   CTD; 5625; -.
DR   DisGeNET; 5625; -.
DR   GeneCards; PRODH; -.
DR   HGNC; HGNC:9453; PRODH.
DR   HPA; HPA020361; -.
DR   MalaCards; PRODH; -.
DR   MIM; 181500; phenotype.
DR   MIM; 239500; phenotype.
DR   MIM; 600850; phenotype.
DR   MIM; 606810; gene.
DR   neXtProt; NX_O43272; -.
DR   Orphanet; 419; Hyperprolinemia type 1.
DR   Orphanet; 3140; Schizophrenia.
DR   PharmGKB; PA33801; -.
DR   eggNOG; KOG0186; Eukaryota.
DR   eggNOG; COG0506; LUCA.
DR   HOVERGEN; HBG008262; -.
DR   InParanoid; O43272; -.
DR   KO; K00318; -.
DR   PhylomeDB; O43272; -.
DR   TreeFam; TF313544; -.
DR   BioCyc; MetaCyc:HS01958-MONOMER; -.
DR   BRENDA; 1.5.99.B2; 2681.
DR   Reactome; R-HSA-70688; Proline catabolism.
DR   UniPathway; UPA00261; UER00373.
DR   ChiTaRS; PRODH; human.
DR   GeneWiki; Proline_oxidase; -.
DR   GenomeRNAi; 5625; -.
DR   PRO; PR:O43272; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000100033; -.
DR   ExpressionAtlas; O43272; baseline and differential.
DR   Genevisible; O43272; HS.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0071949; F:FAD binding; IDA:UniProtKB.
DR   GO; GO:0004657; F:proline dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0019470; P:4-hydroxyproline catabolic process; TAS:BHF-UCL.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; NAS:UniProtKB.
DR   GO; GO:0010942; P:positive regulation of cell death; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006562; P:proline catabolic process; TAS:Reactome.
DR   GO; GO:0010133; P:proline catabolic process to glutamate; IBA:GO_Central.
DR   GO; GO:0006560; P:proline metabolic process; TAS:ProtInc.
DR   Gene3D; 3.20.20.220; -; 2.
DR   InterPro; IPR029041; FAD-linked_oxidoreductase-like.
DR   InterPro; IPR002872; Proline_DH_dom.
DR   InterPro; IPR015659; Proline_oxidase.
DR   PANTHER; PTHR13914; PTHR13914; 1.
DR   Pfam; PF01619; Pro_dh; 1.
DR   SUPFAM; SSF51730; SSF51730; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; FAD; Flavoprotein; Mitochondrion; Oxidoreductase;
KW   Polymorphism; Proline metabolism; Reference proteome; Schizophrenia;
KW   Transit peptide.
FT   TRANSIT       1      ?       Mitochondrion. {ECO:0000255}.
FT   CHAIN         ?    600       Proline dehydrogenase 1, mitochondrial.
FT                                /FTId=PRO_0000025800.
FT   MOD_RES     368    368       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9WU79}.
FT   MOD_RES     486    486       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9WU79}.
FT   VAR_SEQ       1    108       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_021848.
FT   VAR_SEQ       1     84       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10192398,
FT                                ECO:0000303|PubMed:9385373}.
FT                                /FTId=VSP_040848.
FT   VAR_SEQ      85     95       LLARHEQLLYV -> MLEFVMREWKK (in isoform
FT                                3). {ECO:0000303|PubMed:10192398,
FT                                ECO:0000303|PubMed:9385373}.
FT                                /FTId=VSP_040849.
FT   VARIANT       8      8       P -> L.
FT                                /FTId=VAR_064883.
FT   VARIANT      19     19       Q -> P (polymorphism; moderate reduction
FT                                of enzymatic activity; dbSNP:rs2008720).
FT                                /FTId=VAR_064884.
FT   VARIANT      30     30       P -> S.
FT                                /FTId=VAR_064885.
FT   VARIANT      58     58       A -> T.
FT                                /FTId=VAR_064886.
FT   VARIANT     167    167       A -> V (polymorphism; may be a risk
FT                                factor for schizophrenia; moderate
FT                                reduction of enzymatic activity).
FT                                {ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029563.
FT   VARIANT     185    185       R -> Q (polymorphism; mild decrease of
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029564.
FT   VARIANT     185    185       R -> W (polymorphism; moderate reduction
FT                                of enzymatic activity; dbSNP:rs4819756).
FT                                {ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029565.
FT   VARIANT     275    275       T -> N. {ECO:0000269|PubMed:17135275}.
FT                                /FTId=VAR_029874.
FT   VARIANT     289    289       L -> M (in HYRPRO1; mild decrease of
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:12217952,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029566.
FT   VARIANT     406    406       P -> L (in SCZD4; may be associated with
FT                                disease susceptibility; strongly reduced
FT                                enzymatic activity; dbSNP:rs3970555).
FT                                {ECO:0000269|PubMed:11891283,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029567.
FT   VARIANT     426    426       D -> N (in HYRPRO1; moderate reduction of
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029568.
FT   VARIANT     427    427       V -> M (in HYRPRO1 and SCZD4; may be
FT                                associated with disease susceptibility;
FT                                moderate reduction of enzymatic activity;
FT                                dbSNP:rs2238731).
FT                                {ECO:0000269|PubMed:11891283,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029569.
FT   VARIANT     431    431       R -> H (in HYRPRO1; moderate reduction of
FT                                enzymatic activity; dbSNP:rs2904552).
FT                                {ECO:0000269|PubMed:12217952,
FT                                ECO:0000269|PubMed:15662599,
FT                                ECO:0000269|PubMed:17135275}.
FT                                /FTId=VAR_029570.
FT   VARIANT     441    441       L -> P (in HYRPRO1 and SCZD4; may be
FT                                associated with disease susceptibility;
FT                                strongly reduced enzymatic activity;
FT                                dbSNP:rs2904551).
FT                                {ECO:0000269|PubMed:11891283,
FT                                ECO:0000269|PubMed:12217952,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029571.
FT   VARIANT     444    444       G -> D. {ECO:0000269|PubMed:17135275}.
FT                                /FTId=VAR_029875.
FT   VARIANT     453    453       R -> C (in HYRPRO1 and SCZD4; may be
FT                                associated with disease susceptibility;
FT                                strongly reduced enzymatic activity;
FT                                dbSNP:rs3970559).
FT                                {ECO:0000269|PubMed:11891283,
FT                                ECO:0000269|PubMed:12217952,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029572.
FT   VARIANT     455    455       A -> S (in HYRPRO1; mild decrease of
FT                                enzymatic activity; dbSNP:rs1807467).
FT                                {ECO:0000269|PubMed:12217952,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029573.
FT   VARIANT     466    466       T -> M (in SCZD4; may be associated with
FT                                disease susceptibility; strongly reduced
FT                                affinity for FAD; strongly reduced
FT                                enzymatic activity; dbSNP:rs2870984).
FT                                {ECO:0000269|PubMed:11891283,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029574.
FT   VARIANT     472    472       A -> T (in HYRPRO1 and SCZD4; associated
FT                                with disease susceptibility; mild
FT                                decrease of enzymatic activity;
FT                                dbSNP:rs2870983).
FT                                {ECO:0000269|PubMed:11891283,
FT                                ECO:0000269|PubMed:12217952,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029575.
FT   VARIANT     488    488       N -> S (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036566.
FT   VARIANT     521    521       Q -> E (strongly reduced enzymatic
FT                                activity). {ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029576.
FT   VARIANT     521    521       Q -> R (in HYRPRO1 and SCZD4; may be
FT                                associated with disease susceptibility;
FT                                enhanced enzymatic activity;
FT                                dbSNP:rs450046).
FT                                {ECO:0000269|PubMed:11891283,
FT                                ECO:0000269|PubMed:12217952,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15662599}.
FT                                /FTId=VAR_029577.
FT   CONFLICT    144    144       Y -> F (in Ref. 5; AAH94736).
FT                                {ECO:0000305}.
FT   CONFLICT    164    164       T -> S (in Ref. 1; AAB88789).
FT                                {ECO:0000305}.
FT   CONFLICT    343    343       P -> H (in Ref. 5; AAH68260).
FT                                {ECO:0000305}.
FT   CONFLICT    347    347       R -> G (in Ref. 3; AAF21464).
FT                                {ECO:0000305}.
FT   CONFLICT    455    456       AE -> Q (in Ref. 7; AAC39529).
FT                                {ECO:0000305}.
FT   CONFLICT    571    571       L -> F (in Ref. 6; BAD92709).
FT                                {ECO:0000305}.
FT   CONFLICT    588    588       R -> K (in Ref. 7; AAC39529).
FT                                {ECO:0000305}.
FT   CONFLICT    596    596       F -> L (in Ref. 5; AAH68260).
FT                                {ECO:0000305}.
SQ   SEQUENCE   600 AA;  68002 MW;  249E98A0A5BB8027 CRC64;
     MALRRALPAL RPCIPRFVQL STAPASREQP AAGPAAVPGG GSATAVRPPV PAVDFGNAQE
     AYRSRRTWEL ARSLLVLRLC AWPALLARHE QLLYVSRKLL GQRLFNKLMK MTFYGHFVAG
     EDQESIQPLL RHYRAFGVSA ILDYGVEEDL SPEEAEHKEM ESCTSAAERD GSGTNKRDKQ
     YQAHRAFGDR RNGVISARTY FYANEAKCDS HMETFLRCIE ASGRVSDDGF IAIKLTALGR
     PQFLLQFSEV LAKWRCFFHQ MAVEQGQAGL AAMDTKLEVA VLQESVAKLG IASRAEIEDW
     FTAETLGVSG TMDLLDWSSL IDSRTKLSKH LVVPNAQTGQ LEPLLSRFTE EEELQMTRML
     QRMDVLAKKA TEMGVRLMVD AEQTYFQPAI SRLTLEMQRK FNVEKPLIFN TYQCYLKDAY
     DNVTLDVELA RREGWCFGAK LVRGAYLAQE RARAAEIGYE DPINPTYEAT NAMYHRCLDY
     VLEELKHNAK AKVMVASHNE DTVRFALRRM EELGLHPADH QVYFGQLLGM CDQISFPLGQ
     AGYPVYKYVP YGPVMEVLPY LSRRALENSS LMKGTHRERQ LLWLELLRRL RTGNLFHRPA
//
